P1020: Developing and Validating a Clinical Prediction Model Using Biomarkers to Assess Clinical Response and Severity of Crohn@E@s Disease 12 Weeks After Initiation of Biological TherapyECCO'24Year: 2024
Authors: Al-Ali, A.(1);Alamer, A.(2);Alomar, M.(3);Sharrofna, A.(4);Abualrahi, D.(5);Al Lehaibi, L.(3);Alothman, A.(3);Aldosari, S.(2);Alameel, T.(6)*;
(1)Eastern Health Cluster- Dhahran Eye Specialist Hospital, Department of Clinical Pharmacy, Dhahran, Saudi Arabia;(2)College of Pharmacy- Prince Sattam Bin Abdulaziz University, Department of Clinical Pharmacy, Alkharj, Saudi Arabia;(3)Eastern Health Cluster- Dammam Medical Complex, Department of Clinical Pharmacy, Dammam, Saudi Arabia;(4)Eastern Health Cluster- Dammam Medical Complex, Department of Medicine, Dammam, Saudi Arabia;(5)College of Clinical Pharmacy- Imam Abdulrahman Bin Faisal University, Department of Pharmacy Practice, Dammam, Saudi Arabia;(6)King Fahad Specialist Hospital Dammam, Department of Medicine, Dammam, Saudi Arabia;
P1021: Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at one yearECCO'24Year: 2024
Authors: Hancox, S.(1)*;Morda, F.(2);Black, C.(1);Selinger, C.(1);
(1)Leeds Teaching Hospitals NHS Trust, Gastroenterology, Leeds, United Kingdom;(2)Fondazione IRCCS Policlinico San Matteo, Internal Medicine, Pavia, Italy;
P1022: One-year safety and effectiveness of ustekinumab in patients with Crohn’s disease: The K-STAR studyECCO'24Year: 2024
Authors: Lee, C.K.(1);Moon, W.(2);Chun, J.(3);Kim, E.S.(4);Kim, H.W.(5);Yoon, H.(6);Kim, H.S.(7);Lee, Y.J.(8);Choi, C.H.(9);Jung, Y.(10);Park, S.C.(11);Song, G.A.(12);Lee, J.H.(13);Jung, E.S.(14);Kim, Y.(14);Jung, S.Y.(14);Choi, J.M.(14);Ye, B.D.(15)*;
(1)Kyung Hee University Hospital- Kyung Hee University College of Medicine, Gastroenterology- Center for Crohn@E@s and Colitis, Seoul, Korea- Republic Of;(2)Kosin University College of Medicine, Internal Medicine, Busan, Korea- Republic Of;(3)Gangnam Severance Hospital- Yonsei University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(4)School of Medicine- Kyungpook National University, Internal Medicine, Daegu, Korea- Republic Of;(5)Pusan National University Yangsan Hospital, Internal Medicine, Busan, Korea- Republic Of;(6)Seoul National University Bundang Hospital, Internal Medicine, Seongnam, Korea- Republic Of;(7)Chonnam University Medical School, Internal Medicine, Gwangju, Korea- Republic Of;(8)Keimyung University School of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(9)College of Medicine- Chung-Ang University, Internal Medicine, Seoul, Korea- Republic Of;(10)Soonchunhyang University College of Medicine, Internal Medicine, Cheonan, Korea- Republic Of;(11)Kangwon National University School of Medicine, Gastroenterology and Hepatology- Internal Medicine, Chuncheon, Korea- Republic Of;(12)Pusan National University College of Medicine, Internal Medicine, Busan, Korea- Republic Of;(13)Dong-A University Medical Center, Internal Medicine, Busan, Korea- Republic Of;(14)Janssen Korea Ltd., Medical Affairs, Seoul, Korea- Republic Of;(15)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology- Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of;
P1023: Variability in Mesalazine Management for Ulcerative Proctitis Include Doses, Route of Administration and Use of Fecal Calprotectin: Insights from Clinical Practice Across Spain Beyond Clinical GuidelinesECCO'24Year: 2024
Authors: Bastida PazPhD, G.(1)*;Ceballos, D.(2);Ricart, E.(3);Marín-Jiménez, I.(4);Menchén, L.(4);Carpio, D.(5);Ginard, D.(6);Muñoz, F.(7);González-Lama, Y.(8);
(1)La Fe University Hospital, Department of Gastroenterology, Valencia, Spain;(2)Hospital Universitario de Gran Canaria Doctor Negrín, Servicio de Aparato Digestivo, Gran Canaria, Spain;(3)Hospital Clinic de Barcelona, Aparell Digestiu, Barcelona, Spain;(4)Hospital Universitario Gregorio Marañon Madrid, Servicio de Aparato Digestivo, Madrid, Spain;(5)Complexo Hospitalario de Pontevedra, Servicio de Aparato Digestivo, Pontevedra, Spain;(6)Hospital Universitario Son Espases, Servicio de Aparato Digestivo, Palma de Mallorca, Spain;(7)Complejo Asistencial Universitario de Salamanca, Servicio de Aparato Digestivo, Salamanca, Spain;(8)Hospital Unversitario Puerta de Hierro, Servicio de Aparato Digestivo, Madrid, Spain;
P1024: The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review and pooled analysisECCO'24Year: 2024
Authors: Fousekis, F.(1)*;Mpakogiannis, K.(2);Christodoulou, D.(2);Katsanos, K.(2);
(1)University Hospital of Ioannina, Department of Gastroenterology & Hepatology, Ioannina, Greece;(2)University Hospital of Ioannina, Department of Gastroenterology & Hepatology, Ioannina, Greece;
P1027: Optimizing IBD Medication and Therapy: An Interdisciplinary University Outpatient ApproachECCO'24Year: 2024
Authors: Binder, B.(1)*;Elger, T.(1);Huss, M.(1);Loibl, J.(1);Tews, H.C.(1);Kandulski, A.(1);Kratzer, A.(2);Müller, M.(1);Fleischmann, D.(2);
(1)University Hospital Regensburg, Department of Internal Medicine I- Gastroenterology- Hepatology- Endocrinology- Rheumatology and Infectious diseases, Regensburg, Germany;(2)University Hospital Regensburg, Hospital Pharmacy, Regensburg, Germany;
P1029: Prevalance and risk factors of thromboembolism in Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Katı, O.(1);Bakkaloglu, O.K.(2)*;Hatemi, I.(3);Celik, A.F.(3);Seyahi, E.(4);Erzin, Y.(3);
(1)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey;(2)KOSUYOLU HIGH SPECIALIZATION EDUCATION AND RESEARCH HOSPITAL, Gastroenterology, istanbul, Turkey;(3)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;(4)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey;
P102: Neuron-specific gene-2 aggravates colitis and colon tumorigenesis by controlling microbial composition.ECCO'24Year: 2024
Authors: Han, Y.M.(1)*;Jo, K.(2);Lee, C.H.(2);Yu, H.(2);Kim, K.W.(3);Kang, H.W.(3);Kim, J.W.(3);Koh, S.J.(2);
(1)Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine, Seoul, Korea- Republic Of;(2)Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;(3)Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Department of Internal Medicine, Seoul, Korea- Republic Of;
P1030: Inflammatory Bowel Disease helpline contact trends in a real-world Australasian cohort: Crohn’s Colitis Cure (CCC) data insight’s programECCO'24Year: 2024
Authors: Pipicella, J.L.(1,2,3)*;Wilson, W.(4,5);Ghaly, S.(6);Antoniades, S.(6);Kate, L.(7,8);Grafton, R.(7);Ng, W.(9);Sechi, A.(9);Somes, K.(10);Arnold, K.(11);Connor, S.J.(1,2,3,9);Andrews, J.M.(3,7,8);
(1)University of New South Wales, Medicine & Health South Western Sydney Clinical School, Warwick Farm, Australia;(2)Ingham Institute for Applied Medical Research, Gastroenterology- Hepatology and Inflammatory Bowel Disease Research Group, Liverpool, Australia;(3)Crohn@E@s Colitis Cure, CCCure, Pyrmont, Australia;(4)Lyell McEwin Hospital, Anaesthetics, Adelaide, Australia;(5)SA Health, Chief Medical Information Officer, Adelaide, Australia;(6)St Vincent@E@s Hospital Sydney, Gastroenterology, Darlinghurst, Australia;(7)Central Adelaide Local Health Network, Gastroenterology, Adelaide, Australia;(8)University of Adelaide, Faculty of Health and Medical Sciences, Adelaide, Australia;(9)Liverpool Hospital, Gastroenterology and Hepatology, Liverpool, Australia;(10)Campbelltown Hospital, Gastroenterology, Campbelltown, Australia;(11)Christchurch Hospital, Gastroenterology, Christchurch Central City, New Zealand;
P1031: Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis treated with upadacytynib.ECCO'24Year: 2024
Authors: Kaniewska, M.(1)*;Krogulecki, M.(2);Lewandowski, K.(3);Filipiuk, A.(2);Gonciarz, M.(2);Rydzewska, G.(3);
(1)National Medical Institute of the Ministry of Interior and Administration, Clinical Department of Internal Medicine and Gastroenterology, Warsaw, Poland;(2)Military Institute of Medicine-National Research Institute- Warsaw- Poland, Clinical Department of Gastroenterology and Internal Medicine, Warsaw, Poland;(3)National Medical Institute of the Ministry of Interior and Administration- Warsaw- Poland, Clinical Department of Internal Medicine and Gastroenterology, Warsaw, Poland;
P1032: Ileoanal Pouch Salvage Rates with Endoluminal Vacuum Therapy for Early vs. Late Anastomotic LeaksECCO'24Year: 2024
Authors: Alipouriani, A.(1);Lavryk , O.(1);Lipman , J.(1);Hull, T.(1);Steele, S.(1);Liska , D.(1);Holubar, S.(1)*;
(1)Cleveland Clinic Foundation, Department of Colorectal surgery, Cleveland, United States;
P1033: Road to exit strategy in patients with inflammatory bowel disease: ready or not?ECCO'24Year: 2024
Authors: Todeschini, A.(1)*;Ciccocioppo, R.(2);Geccherle, A.(1);Bernuzzi, M.(2);Signoretto, P.(1);Colaci, N.(3);Barugola, G.(4);Variola, A.(1);
(1)IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar di Valpolicella, Italy;(2)A.O.U.I. Policlinico G.B. Rossi and University of Verona, Gastroenterology Unit, Verona, Italy;(3)IRCCS Sacro Cuore Don Calabria, Clinical Research, Negrar di Valpolicella, Italy;(4)IRCCS Sacro Cuore Don Calabria, General Surgery, Negrar di Valpolicella, Italy;
P1035: CT-based radiomics signature of visceral adipose tissue and bowel lesions for identifying patients with Crohn’s disease resistant to infliximabECCO'24Year: 2024
Authors: Wang, Y.(1)*;Zhou, Z.(2);Luo, Z.(3);Li, X.(1);
(1)The First Affiliated Hospital of Sun Yat-Sen University, Department of Radiology, Guangzhou, China;(2)Sun Yat-Sen University, Zhongshan School of Medicine, Guangzhou, China;(3)Shenzhen University Medical School, Medical AI Lab- School of Biomedical Engineering, Shenzhen, China;
P1036: Persistence of biologics and advanced small molecules in 4th, 5th and 6th line of therapy for inflammatory bowel disease: a cross-sectional retrospective studyECCO'24Year: 2024
Authors: ParigiMD, T.L.(1)*;Massimino, L.(1);Carini, A.(1);Allocca, M.(1);D@E@Amico, F.(1);Furfaro, F.(1);Zilli, A.(1);Cagliani, S.(1);Errico, C.(1);Facoetti, A.(1);Nicolò, S.(1);Peyrin-Biroulet, L.(2);Danese, S.(1);
(1)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(2)University of Lorraine, Inserm- NGERE- F-54000, Nancy, Italy;
P1037: Treatment sequences and time on specific treatments in patients with inflammatory bowel disease under advanced treatment – a German claims data analysisECCO'24Year: 2024
Authors: Dignass, A.(1)*;Teich, N.(2);Kudernatsch, R.(3);Sünwoldt, J.(3);Grellmann, C.(4);Sende, F.(4);Kaiser, S.(3);
(1)Agaplesion Markus Krankenhaus, Medizinische Klinik I, Frankfurt/Main, Germany;(2)Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten, n/a, Leipzig, Germany;(3)Takeda Pharma Vertrieb GmbH & Co. KG, n/a, Berlin, Germany;(4)WIG2 Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung, n/a, Leipzig, Germany;
P1038: Does combination immunomodulator therapy impact real-world biologic effectiveness in Inflammatory Bowel Diseases?A propensity score analysis in patients treated with anti-TNF and non-anti-TNF biologics in the UK IBD BioResourceECCO'24Year: 2024
Authors: Desoki, R.(1,2)*;Kapizioni, C.(1,3);Lam, D.(1,4);Balendran, K.(1,5);Al-Sulais, E.(1,6);Subramanian, S.(1);Pele, L.(7,8);Parkes, M.(1);Raine, T.(1);
(1)Cambridge University Hospital, Department of Gastroenterology, Cambridge, United Kingdom;(2)Alexandria University, Department of Genetics, Alexandria, Egypt;(3)Attikon University Hospital, Department of Gastroenterology, Athens, Greece;(4)Sir Charles Gairdner Hospital, Department of Gastroenterology, Perth, Australia;(5)University of Jaffna, Department of Clinical Medicine, Jaffna, Sri Lanka;(6)King Fahad Specialist Hospital, Department of Gastroenterology, Dammam, Saudi Arabia;(7)University of Cambridge, Department of Medicine, Cambridge, United Kingdom;(8)IBD BioResource, NIHR BioResource, Cambridge, United Kingdom;
